JP2022137237A5 - - Google Patents

Download PDF

Info

Publication number
JP2022137237A5
JP2022137237A5 JP2022113736A JP2022113736A JP2022137237A5 JP 2022137237 A5 JP2022137237 A5 JP 2022137237A5 JP 2022113736 A JP2022113736 A JP 2022113736A JP 2022113736 A JP2022113736 A JP 2022113736A JP 2022137237 A5 JP2022137237 A5 JP 2022137237A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
salt
salt according
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022113736A
Other languages
English (en)
Japanese (ja)
Other versions
JP7288540B2 (ja
JP2022137237A (ja
Filing date
Publication date
Priority claimed from JP2021543495A external-priority patent/JP7061236B2/ja
Application filed filed Critical
Publication of JP2022137237A publication Critical patent/JP2022137237A/ja
Publication of JP2022137237A5 publication Critical patent/JP2022137237A5/ja
Priority to JP2023086862A priority Critical patent/JP7525693B2/ja
Application granted granted Critical
Publication of JP7288540B2 publication Critical patent/JP7288540B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022113736A 2019-01-22 2022-07-15 Ｍｔｏｒｃモジュレーターおよびその使用 Active JP7288540B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023086862A JP7525693B2 (ja) 2019-01-22 2023-05-26 Ｍｔｏｒｃモジュレーターおよびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962795482P 2019-01-22 2019-01-22
US62/795,482 2019-01-22
JP2021543495A JP7061236B2 (ja) 2019-01-22 2020-01-22 Ｍｔｏｒｃモジュレーターおよびその使用
PCT/US2020/014671 WO2020154447A1 (en) 2019-01-22 2020-01-22 Mtorc modulators and uses thereof
JP2022067435A JP7108804B2 (ja) 2019-01-22 2022-04-15 Ｍｔｏｒｃモジュレーターおよびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022067435A Division JP7108804B2 (ja) 2019-01-22 2022-04-15 Ｍｔｏｒｃモジュレーターおよびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023086862A Division JP7525693B2 (ja) 2019-01-22 2023-05-26 Ｍｔｏｒｃモジュレーターおよびその使用

Publications (3)

Publication Number Publication Date
JP2022137237A JP2022137237A (ja) 2022-09-21
JP2022137237A5 true JP2022137237A5 (enExample) 2023-01-20
JP7288540B2 JP7288540B2 (ja) 2023-06-07

Family

ID=71737003

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2021543495A Active JP7061236B2 (ja) 2019-01-22 2020-01-22 Ｍｔｏｒｃモジュレーターおよびその使用
JP2022067435A Active JP7108804B2 (ja) 2019-01-22 2022-04-15 Ｍｔｏｒｃモジュレーターおよびその使用
JP2022113736A Active JP7288540B2 (ja) 2019-01-22 2022-07-15 Ｍｔｏｒｃモジュレーターおよびその使用
JP2023086862A Active JP7525693B2 (ja) 2019-01-22 2023-05-26 Ｍｔｏｒｃモジュレーターおよびその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2021543495A Active JP7061236B2 (ja) 2019-01-22 2020-01-22 Ｍｔｏｒｃモジュレーターおよびその使用
JP2022067435A Active JP7108804B2 (ja) 2019-01-22 2022-04-15 Ｍｔｏｒｃモジュレーターおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023086862A Active JP7525693B2 (ja) 2019-01-22 2023-05-26 Ｍｔｏｒｃモジュレーターおよびその使用

Country Status (14)

Country Link
US (4) US11230557B2 (enExample)
EP (2) EP4272825A3 (enExample)
JP (4) JP7061236B2 (enExample)
KR (2) KR102705165B1 (enExample)
CN (3) CN116947884B (enExample)
AU (3) AU2020210921B2 (enExample)
BR (1) BR112021014479A2 (enExample)
CA (2) CA3236782A1 (enExample)
EA (1) EA202191983A1 (enExample)
GB (3) GB2586427B (enExample)
IL (2) IL315399A (enExample)
MX (2) MX2021008777A (enExample)
WO (1) WO2020154447A1 (enExample)
ZA (3) ZA202105847B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
EP4272825A3 (en) 2019-01-22 2023-12-06 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
BR112022010754A2 (pt) * 2019-12-05 2022-08-23 Anakuria Therapeutics Inc Análogos de rapamicina e usos dos mesmos
MX2022011964A (es) 2020-03-27 2022-12-02 Aeovian Pharmaceuticals Inc Moduladores de mtorc1 y usos de los mismos.
CN116322677B (zh) * 2020-07-21 2025-09-23 艾奥维安制药公司 Mtorc1调节剂及其用途
CN116917294A (zh) * 2021-01-22 2023-10-20 詹森药业有限公司 雷帕霉素类似物及其用途
JP2024503898A (ja) * 2021-01-22 2024-01-29 ヤンセン ファーマシューティカ エヌ．ベー． ラパマイシン類似体及びその使用
EP4594329A1 (en) * 2022-09-30 2025-08-06 Biotronik Ag Synthesis and characterization of cyclic hydrocarbon esters of everolimus

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
CH677886A5 (enExample) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
PT734389E (pt) * 1993-12-17 2000-09-29 Novartis Ag Derivados de rapamicina uteis como imunossupressores
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
FR2730932B1 (fr) 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
CZ292233B6 (cs) 1995-06-09 2003-08-13 Novartis Ag Deriváty rapamycinu a jejich použití jako léčiv
FR2742676B1 (fr) 1995-12-21 1998-02-06 Oreal Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie
DK0910633T3 (da) 1996-07-05 2010-03-29 Biotica Tech Ltd Hybrid polyketidsyntase I-gen
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
FR2755854B1 (fr) 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
FR2760970B1 (fr) 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
FR2787027B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787026B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr) 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr) 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2789076B1 (fr) 1999-02-02 2001-03-02 Synthelabo Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
CA2405958C (en) 2000-04-13 2011-08-09 Biotica Technology Limited Hybrid glycosylated products and their production and use
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
AU2002241823A1 (en) 2001-01-11 2002-07-24 Eastman Chemical Company Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
FR2819427B1 (fr) 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
AU2002367976B2 (en) 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
GB0128680D0 (en) 2001-11-29 2002-01-23 Biotica Tech Ltd Hybrid glycosylated products and their production and use
ES2296063T3 (es) 2002-07-16 2008-04-16 Biotica Technology Limited Produccion de poliquetidos y otros productos naturales.
US7476393B2 (en) 2002-11-29 2009-01-13 L'oreal Process for the preparation of a cationic nanoemulsion, and cosmetic composition
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US7468402B2 (en) 2004-03-17 2008-12-23 Baker Hughes Incorporated Polymeric nanoemulsion as drag reducer for multiphase flow
SG158143A1 (en) * 2004-12-20 2010-01-29 Wyeth Corp Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
EP1896075A2 (en) * 2005-06-22 2008-03-12 LifeCycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
GB0601406D0 (en) 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
WO2009131631A1 (en) * 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
AU2008364165B2 (en) 2008-11-11 2015-01-29 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Inclusion complexes of pinocembrin with cyclodextrin or its derivatives
EP2675450B1 (en) 2011-02-16 2016-02-10 Novartis AG Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
CN102731527A (zh) * 2012-07-12 2012-10-17 浙江医药股份有限公司新昌制药厂 一种西罗莫司42－醚衍生物的合成方法
WO2014153118A1 (en) 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
WO2016040806A1 (en) * 2014-09-11 2016-03-17 The Regents Of The University Of California mTORC1 INHIBITORS
CN104341434B (zh) * 2014-10-16 2016-04-06 福建省微生物研究所 取代的雷帕霉素三氮唑衍生物和用途
AU2016315653A1 (en) * 2015-08-28 2018-03-15 Buck Institute For Research On Aging Rapamycin analogs showing improved mTORC1 specificity
WO2017038925A1 (ja) * 2015-09-03 2017-03-09 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN108926533B (zh) * 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
WO2020076738A2 (en) 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
AU2019374812B2 (en) 2018-11-06 2025-03-06 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
JP7618553B2 (ja) 2018-12-18 2025-01-21 ノバルティス アーゲー ラパマイシン誘導体
EP4272825A3 (en) * 2019-01-22 2023-12-06 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
BR112022010754A2 (pt) 2019-12-05 2022-08-23 Anakuria Therapeutics Inc Análogos de rapamicina e usos dos mesmos
MX2022011964A (es) 2020-03-27 2022-12-02 Aeovian Pharmaceuticals Inc Moduladores de mtorc1 y usos de los mismos.
CN116322677B (zh) 2020-07-21 2025-09-23 艾奥维安制药公司 Mtorc1调节剂及其用途
JP2024503898A (ja) 2021-01-22 2024-01-29 ヤンセン ファーマシューティカ エヌ．ベー． ラパマイシン類似体及びその使用

Similar Documents

Publication Publication Date Title
JP2020169171A5 (enExample)
JP2021514001A5 (enExample)
JP2024504932A5 (enExample)
ES2922973T1 (es) Peptidos funcionalizados como agentes antivirales
JP2010501584A5 (enExample)
JP2022545633A5 (enExample)
JP2025512474A5 (enExample)
JP2022522694A5 (enExample)
JP2021527125A5 (enExample)
JP2023553835A5 (enExample)
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
RU2005128190A (ru) Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации
JP2021528488A5 (enExample)
JP2006528643A5 (enExample)
JP2011509309A5 (enExample)
JP2013532652A5 (enExample)
JP2020075939A5 (enExample)
JP2021046404A5 (enExample)
JP2022529321A5 (enExample)
JP2008536833A5 (enExample)
JP2025502943A5 (enExample)
JP2025505200A5 (enExample)
JP2023553428A5 (enExample)
JP2007514691A5 (enExample)